Improving the standard of care for people living with liver disease
Hepatic Health represents a new educational resource from Gilead Sciences and is designed to meet the educational needs of healthcare professionals and people with an interest in the field of liver disease; particularly with regard to chronic hepatitis C virus (HCV) infection, hepatitis B virus (HBV) infection, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) with progressive fibrosis and advanced fibrosis.
Hepatic Health is a reflection of Gilead’s ongoing commitment to advancing the care of people with liver disease.
The importance of clinical context in hepatitis B screening
In an exclusive interview for Hepatic Health, Dr Patrick Kennedy, consultant hepatologist, discusses the importance of clinical context when diagnosing hepatitis B (HBV). In the article and video, Dr Kennedy explains the need for further investigation when presented with abnormal liver function test (LFTs) results, and why clinical context can mean normal LFT results warrant more exploration.Find out more
Looking for in-depth information on liver disease?
Background on the global and local burden of HCV; the expanding role of primary care in HCV management; diagnosis and pre-treatment assessment; HCV treatment and ongoing care. The important role of hepatitis nurses in the HCV care pathway is also discussed.
A comprehensive summary of currently available knowledge on HBV is provided here – information focuses on screening, diagnosis and management of people living with HBV.
NAFLD & NASH
The aim of this section is to summarise the most recent data on NAFLD and NASH including the burden, staging, diagnosis and management approaches such as lifestyle interventions and multidisciplinary management.
An educational resource designed to meet the needs of healthcare professionals and people with an interest in liver disease
Providing relevant information across the care continuum
Hepatic Health can assist healthcare professionals of many specialities, including:
- Addiction specialists
- Hepatitis nurses
- Infectious disease physicians
- Primary care providers
All aspects of screening, evaluation and treatment of HCV, HBV, NAFLD and NASH with progressive fibrosis are addressed, including expert insights on complex issues and scientific updates from annual meetings.
Gilead R&D has helped advance the treatment of chronic hepatitis C infection, and helped manage chronic hepatitis B infection. Today, the company’s liver disease research focuses on advancing the care of patients living with liver diseases through its research and development efforts.
Discover liver disease content related to specific areas of interest, including addiction and harm reduction and primary care.